Urethral PeRfusion Index-Guided Hemodynamic ManagemenT in Patients Having Major Abdominal Surgery: the UPRIGHT Randomized Feasibility Trial
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jan 23, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The UPRIGHT trial is a study designed to explore how well we can monitor blood flow in the body during major abdominal surgery using a method called the urethral perfusion index. This measurement helps us understand how well tissues are getting the blood they need. In this trial, some patients will have their urethral perfusion index carefully maintained during surgery, while others will receive routine care without specific monitoring. The researchers want to see if the patients with careful monitoring have better blood flow in their tissues compared to those receiving standard care.
To be eligible for this trial, participants need to be at least 45 years old and scheduled for a major abdominal surgery that is expected to last at least two hours. They also need to have medical reasons for using an arterial catheter (a small tube inserted into an artery to monitor blood pressure) and a urinary catheter. However, individuals who are pregnant, are having certain types of surgeries like kidney or liver transplants, or have had previous surgeries on the urethra or bladder are not eligible. Participants can expect to be closely monitored during their surgery and will contribute to important research that could improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • at least 45 years old
- • scheduled for elective major abdominal surgery (involving visceral organs with an expected duration of at least 120 minutes)
- • indication for an arterial catheter
- • indication for an urinary catheter
- Exclusion Criteria:
- • Pregnancy
- • Planned surgery: nephrectomy, liver or kidney transplantation surgery
- • Patients who previously had surgery on the urethra or bladder
- • Patients without clinical indication for continuous blood pressure monitoring with an intraarterial catheter
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Bernd Saugel, MD
Principal Investigator
University Medical Center Hamburg Eppendorf, Hamburg, Germany and OUTCOMES RESEARCH Consortium®, Houston, Texas, USA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported